Benzhydryl Compounds; Diabetes Mellitus, Type 2/drug therapy; Glucosides/pharmacology/therapeutic use; Humans; Sodium-Glucose Transport Proteins/antagonists & inhibitors
Abstract :
[en] Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete glucose in urine when hyperglycaemia exceeds tubular reabsorption threshold. Such reabsorption depends on sodium-glucose cotransporters-2 (SGLT2), which can be blocked by selective inhibitors. These pharmacological agents augment glucosuria and reduce hyperglycaemia independently of insulin. Some have already proven their efficacy to improve glucose control, in monotherapy or in combination, while promoting weight loss and without inducing hypoglycaemia. Dapagliflozin should be the first medication of this new pharmacological class to be commercialized for the management of type 2 diabetes.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Service de diabétologie, nutrition, maladies métaboliques
Radermecker, Régis ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Ernest, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Pharmacologie clinique
Jandrain, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Language :
French
Title :
Inhibiteurs du cotransporteur du glucose SGLT2 renal pour traiter le diabete de type 2.
Alternative titles :
[en] Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes
De Fronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Scheen A, Radermecker R, Philips J, et al. Les incré tinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse 2007;3:1884, 1886-8.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications. Diabet Med 2010;27:136-42.
Abdul-Ghani MA, Norton LDe Fronzo RA. Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:513-31.
Chao E, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-9.
Nair S,Wilding J. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42.
Brooks AM,Thacker SM. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2009;43:1286-93.
Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196-8.
Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6.
Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14.
Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47-54.
Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-9.
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7.
Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24.
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:2223-33.
Bailey CJ, Gross JL, Yadav M, et al. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone. Diabetes 2011;60:Abstract 0988-P.
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011 Aug 4. (Epub ahead of print).
Nauck M, Del Prato S, Rohwedder K, et al. Longterm efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Diabetes 2011;60(Suppl. 1): Abstract 0040-LB.
Strojek K, Yoon K, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomised, 24-week, double-blind, placebp-controlled trial. Diabetes Obes Metab 2011;doi:10.1111/j.1463-1326.2011.01434.x.(Epub ahead of print).
Rosenstock J, Vico M, Wei L, et al. Dapagliflozin added-on to pioglitzone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes. Diabetes 2011;60(Suppl. 1):Abstract 0986-P.
Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62.
Wilding JPH, Woo V, Pahor A, et al. Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia 2010;53(Suppl. 1):S348, 871.
Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-6.
Parikh SJ, Johnsson KM, Ptaszynska A, et al. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria. Diabetes 2011;60(Suppl. 1):Abstract 0984-P.
Patel AK, Fonseca V. Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. Curr Diab Rep 2010;10:101-7.
Nicolle L, Usiskin K, Capuano G, Ways K. No increase in bacteriuria or urinary tract infections in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, a sodium glucose co-transporter (SGLT2) inhibitor. Diabetes 2011;60 (Suppl. 1):Abstract 0043-LB.
Scheen A. Exenatide once weekly in type 2 diabetes. Lancet 2008;372:1197-8.
Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72.
Aires I, Calado J. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs 2010;11:1182-90.
